Author: Customer Service

WASHINGTON, Nov. 07, 2025 (GLOBE NEWSWIRE) — Quantum Leap Energy LLC (“QLE”), a wholly-owned subsidiary of ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or “ASPI” or the “Company”), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced that QLE has commenced an offering of QLE’s convertible notes in a private placement to accredited investors and certain non-U.S. persons. QLE has entered into a definitive convertible note purchase agreement with certain investors for an initial closing of US$64.3 million aggregate principal amount of QLE’s convertible notes (the “Notes”). The issuance of Notes pursuant to the offering will result in the automatic conversion of QLE’s outstanding convertible promissory notes originally issued...

West Coast-Born Pizza Franchise Continues Expansion in Texas with Round Rock, TX Opening LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Round Table Pizza and 17 other restaurant concepts, has announced the opening of its first Round Table Pizza in the Greater Austin area in Round Rock, TX. “Our opening in Round Rock marks another exciting milestone for the brand, our first restaurant in the Greater Austin area,” said David Pear, President of Round Table Pizza. “Round Table Pizza has developed a strong following across the state with 5 locations to date, and we are eager to continue building on that momentum by bringing our premium pizzas and unmatched dining experience to the Round Rock community.” Since its founding in 1959, Round Table Pizza has been recognized as “Pizza...

SOUTHAMPTON, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) — Environmental Tectonics Corporation’s (OTCID: ETCC) (“ETC” or the “Company”) Environmental Testing and Simulation Systems (“ETSS”) business unit announced it has been awarded a $7.0 million contract as the environmental test cell equipment supplier for a new, state-of-the-art F1 and NASCAR Racing engine development center. The contract includes the supply of a variety of test cell support equipment including combustion air supply systems that provide precisely controlled temperature, humidity and pressure conditions at the engine intake. ETSS was also recently awarded a $2.1 million contract as the testing equipment supplier for a U.S. based, heavy duty diesel engine developer. This equipment will provide precisely conditioned combustion air as well as altitude simulation up to...

Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted modulation of immunosuppressive myeloid cells, including tumor-associated macrophages (TAMs) Pre-clinical data for IO Biotech’s additional T-win vaccine candidate, IO170 targeting Transforming Growth Factor (TGF)-β, demonstrates induction of immune responses that could inhibit tumor growth and reduce lung metastasis Data presented at the Society for Immunotherapy of Cancer’s Annual MeetingNEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced new pre-clinical data...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1 Evidence of immune activation and tumor-immune remodeling underscore agenT-797’s potential to restore responsiveness in PD-1–resistant disease Favorable safety and reproducible activity reinforce MiNK’s leadership in allogeneic iNKT cell therapyNEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to reconstitute immunity to treat cancer and immune disorders, today announced updated clinical results evaluating agenT-797, alone and in combination with anti-PD-1 therapy, in patients with advanced solid tumors refractory to all...

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — BioAge Labs, Inc. (NASDAQ: BIOA) (“BioAge”, “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 – 7:55 AM ET (12:30 – 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcast will be available in the investor section of the Company’s website at https://ir.bioagelabs.com/, and...

WEST HARTFORD, Conn., Nov. 07, 2025 (GLOBE NEWSWIRE) — Legrand®, a global leader in electrical and digital building infrastructures, announced that it has acquired Avtron Power Solutions, a leading global provider of load banks and power quality solutions that serve a wide range of high-growth markets where reliable delivery of power is required. Avtron employs 600 people, operates five sites across North America and Europe, and is expected to generate nearly $350 million in revenue in 2025. With a commitment to innovation and quality, Avtron delivers dependable solutions for datacenters, healthcare facilities, renewable energy applications and industrial manufacturing sites to ensure that critical power is available when it’s needed by customers worldwide. Avtron will operate as a stand-alone business unit within Legrand’s Electrical...

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open). During the call, members of the NTHI management team and independent members of the company’s Scientific Advisory Board (SAB) will present data updates from the Company’s ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program, evaluating intranasal delivery of NEO100 (high-purity perillyl alcohol) in patients with recurrent high grade malignant...

– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors “hot” REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — Coherus Oncology, Inc. (NASDAQ: CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic HNSCC. These data are being presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November...